Heterogeneity of Brain Heart Infusion agar media (BHI): Effects on the determination of the vancomycin and the teicoplanin minimal inhibitory concentrations (MIC) of Staphylococcus aureus strains;Hétérogénéité des milieux gélosés cœur-cervelle (BHI): Effets sur la détermination des concentrations minimales inhibitrices (CMI) à la vancomycine et à la teicoplanine des souches de Staphylococcus aureus

Pathologie Biologie

Volumn 52, Issue 8, 2004, Pages 450-454

  Martin, C ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Concentration minimale inhibitrice; E test; Glycopeptides; Minimal inhibitory concentration; Staphylococcus aureus

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

AGAR MEDIUM; ANALYSIS OF VARIANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; BRAIN; CULTURE MEDIA; HEART; HUMANS; MICROBIAL SENSITIVITY TESTS; REAGENT KITS, DIAGNOSTIC; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 4744373255     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.07.031     Document Type: Article

References (20)

1. J.L. Mainardi, D.M. Shlaes, J.H. Goering, J.H. Shlaes, J.F. Acar, and F.W. Goldstein Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus J. Inf. Dis. 171 1995 1646 1650
2. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J. Antimicrob. Chemoth. 40 1997 135 136
3. O. Denis, C. Nonhoff, B. Baudouin, C. Knoop, S. Bobin-Dubreux, and M.J. Struelens Remergence of vancomycin-intermediate Staphylococus aureus in a belgian hospital: microbiological and clinical features J. Antimicrob. Chemoth. 50 2002 383 391
4. A. Srinivasan, J.D. Dick, and T.M. Perl Vancomycin resistance in staphylococci Clin. Microbiol. Rev. 15 2002 430 438
5. T. Villevieille, I. Vincenti-Rouquette, J.L. Koeck, F. Petitjeans, J.M. Rousseau, and L. Brinquin Septicmie fatale Staphylococcus aureus de sensibilit diminue aux glycopeptides Ann. Fr. Reanim. 20 2001 498 500
6. J. Pofelski, P. Pavese, J.P. Brion, C. Marrakchi, E. Gay, and C. Recule Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides Therapeutic indications Presse Med. 32 2003 217 220
7. S.K. Hubert, J.M. Mohammed, S.K. Fridkin, R.P. Gaynes, J.E. McGowan Jr., and F.C. Tenover Glycopeptide intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospital J. Clin. Microbiol. 50 1999 3590 3593
8. T.R. Walsh, A. Bolmstrm, A. Qwarnstrm, P. Ho, M. Wootton, and R.A. Howe valuation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides J. Clin. Microbiol. 39 2001 2439 2444
9. L. Bernard, P. Vaudaux, P. Rohner, E. Huggler, M. Armanet, and D. Pittet Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains J. Microbiol. Meth. 39 2004 231 239
10. F. Gurin, A. Buu-Ho, J.L. Mainardi, G. Kac, N. Colardelle, and S. Vaupr Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in parisian hospital J. Clin. Microbiol. 9 2000 2985 2988
11. A. Carricajo, F. Mallaval, N. Fonsale, A.C. Vautrin, and G. Aubert Recherche de Staphylococcus aureus de sensibilit diminue aux glycopeptides dans un hpital universitaire (juin 1999fvrier 2000) Med. Mal. Infect. 31 2001 681 683
12. M.E. Reverdy, S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, and G. Lina Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospital Clin. Microbiol. Infect. 7 2001 267 272
13. E. Lecaillon, P. Gueudet, M. Wooton, T.R. Walsh, A.P. MacGowan, and M.P. Jones Situation endmique Staphylococcus aureus de sensibilit diminue aux glycopeptides constitus de clones varis et sans relation avec un traitement la vancomycine Pathol. Biol. 51 2002 525 529
14. G.L. Cartalano, M. Cheron, D. Benabid, M. Leneveu, and A. Boisivon Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals Clin. Microbiol. Infect. 10 2004 448 451
15. F.O. Mallaval, A. Carricajo, I. Martin, N. Fonsale, F. Grattard, and P. Fascia Contrle de phnomnes pidmiques dus des souches de Staphylococcus aureus de sensibilit diminue aux glycopeptides Pathol. Biol. 51 2003 469 473
16. N. El Sohl, M. Davi, A. Morvan, H. Aubry-Damon, and N. Marty Characteristic of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides J. Antimicrob Chemoth. 52 2003 691 694
17. Communiqu 2004 2004 SFM 32 34
18. J. Ariza, M. Pujol, J. Cabo, C. Pena, N. Fernandez, and J. Linares Vancomycin in surgical infections due to methicillinresistant Staphylococcus aureus with heterogeneous resistance to vancomycin Lancet 353 1999 1587 1588
19. K. Hiramatsu, N. Aritaka, H. Hanaki, T. Ino, S. Kawasaki, and Y. Hosoda Dissemination in Japanese hospitals strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1999 1670 1673
20. T.R. Walsh, and R.A. Howe The prevalence and mechanism of vancomycin resistance in Staphylococcus aureus Annu. Rev. Microbiol. 56 2002 657 675